Advertisement

International Journal of Clinical Oncology

, Volume 24, Issue 11, pp 1377–1384 | Cite as

Efficacy of chemotherapy for older patients with gastric cancer: a multicenter retrospective cohort study

  • Yoshito Hayashi
  • Tsutomu Nishida
  • Shusaku Tsutsui
  • Takashi Ohta
  • Shinjiro Yamaguchi
  • Masayoshi Horimoto
  • Eiji Masuda
  • Hiroyuki Narahara
  • Aya Sugimoto
  • Yoshiki Tsujii
  • Kunio Suzuki
  • Hideki Hagiwara
  • Hideki Iijima
  • Tetsuo TakeharaEmail author
Original Article
  • 89 Downloads

Abstract

Background

Gastric cancer is one of the leading causes of malignant disease-related mortality, worldwide. With the use of recently developed anti-tumor agents, the prognoses of patients with unresectable gastric cancer are improving. However, the development of an aggressive treatment strategy for older patients (OPs) remains under debate due to concerns regarding treatment feasibility or patient frailty. We aimed to elucidate whether aggressive chemotherapy has survival benefits for OPs with advanced gastric cancer.

Methods

We analyzed consecutive patients diagnosed with inoperable advanced gastric cancer across seven hospitals from August 2007 to July 2015. We defined OPs as patients aged 75 years or older and compared their survival rates with those of non-older patients (NPs).

Results

A total of 256 OPs and 425 NPs were enrolled. Of the OPs, 152 patients received chemotherapy and 104 patients received best supportive care (BSC). In contrast, among the NPs, 375 patients received chemotherapy and 50 patients received BSC. There was no significant difference of the median survival time between OPs and NPs in the response to BSC (61 vs 43 days) or chemotherapy (312 vs 348 days). Combination chemotherapy significantly improved survival compared to monotherapy in both OPs and NPs groups (382 vs 253 days in OPs, 381 vs 209 days in NPs). Good performance status, combination therapy, and male, but not age, were significant independent prognostic factors.

Conclusion

When the performance status of a gastric cancer patient is good, active chemotherapy may improve survival, regardless of age.

Keywords

Gastric cancer Older patients Chemotherapy Best supportive care 

Notes

Compliance with ethical standards

Conflict of interest

All author declare that they have no conflict of interest.

References

  1. 1.
    Pilleron S, Sarfati D, Janssen-Heijnen M et al (2019) Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer 144:49–58CrossRefGoogle Scholar
  2. 2.
    Walko CM, McLeod HL (2014) Personalizing medicine in geriatric oncology. J Clin Oncol 32:2581–2586CrossRefGoogle Scholar
  3. 3.
    Bertuccio P, Chatenoud L, Levi F et al (2009) Recent patterns in gastric cancer: a global overview. Int J Cancer 125:666–673CrossRefGoogle Scholar
  4. 4.
    Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221CrossRefGoogle Scholar
  5. 5.
    Sachlova M, Majek O, Tucek S (2014) Prognostic value of scores based on malnutrition or systemic inflammatory response in patients with metastatic or recurrent gastric cancer. Nutr Cancer 66:1362–1370CrossRefGoogle Scholar
  6. 6.
    Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824–1831CrossRefGoogle Scholar
  7. 7.
    Rodin MB, Mohile SG (2007) A practical approach to geriatric assessment in oncology. J Clin Oncol 25:1936–1944CrossRefGoogle Scholar
  8. 8.
    Sasaki Y, Iwasa S, Okazaki S et al (2017) A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer. Gastric Cancer 21:439–445CrossRefGoogle Scholar
  9. 9.
    Terazawa T, Iwasa S, Takashima A et al (2013) Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer. J Cancer Res Clin Oncol 139:2111–2116CrossRefGoogle Scholar
  10. 10.
    Koizumi W, Takiuchi H, Yamada Y et al (2010) Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol 21:1001–1005CrossRefGoogle Scholar
  11. 11.
    Bando H, Yamada Y, Tanabe S et al (2016) Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer 19:919–926CrossRefGoogle Scholar
  12. 12.
    Hwang IG, Ji JH, Kang JH et al (2017) A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol 8:170–175CrossRefGoogle Scholar
  13. 13.
    Kelly CM, Power DG, Lichtman SM (2014) Targeted therapy in older patients with solid tumors. J Clin Oncol 32:2635–2646CrossRefGoogle Scholar
  14. 14.
    Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697CrossRefGoogle Scholar
  15. 15.
    Kimura Y, Fujii M, Masuishi T et al (2018) Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). Gastric Cancer 21:421–427CrossRefGoogle Scholar
  16. 16.
    Imamura H, Kishimoto T, Takiuchi H et al (2014) Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). J Chemother 26:57–61CrossRefGoogle Scholar
  17. 17.
    Kim HS, Kim JH, Kim JW et al (2016) Chemotherapy in elderly patients with gastric cancer. J Cancer 7:88–94CrossRefGoogle Scholar
  18. 18.
    Kim ST, Park KH, Oh SC et al (2012) Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients? Asia Pac J Clin Oncol 8:194–200CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Yoshito Hayashi
    • 1
  • Tsutomu Nishida
    • 2
  • Shusaku Tsutsui
    • 3
  • Takashi Ohta
    • 4
  • Shinjiro Yamaguchi
    • 4
  • Masayoshi Horimoto
    • 5
  • Eiji Masuda
    • 6
  • Hiroyuki Narahara
    • 7
  • Aya Sugimoto
    • 2
  • Yoshiki Tsujii
    • 1
  • Kunio Suzuki
    • 5
  • Hideki Hagiwara
    • 4
  • Hideki Iijima
    • 1
  • Tetsuo Takehara
    • 1
    Email author
  1. 1.Department of Gastroenterology and HepatologyOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Department of GastroenterologyToyonaka Municipal HospitalToyonakaJapan
  3. 3.Department of GastroenterologyItami City HospitalItamiJapan
  4. 4.Department of GastroenterologyKansai Rosai HospitalAmagasakiJapan
  5. 5.Department of GastroenterologySaiseikai Senri HospitalSuitaJapan
  6. 6.Department of GastroenterologyNational Hospital Organization Osaka Minami National HospitalKawachinaganoJapan
  7. 7.Department of GastroenterologyHyogo Prefectural Nishinomiya HospitalNishinomiyaJapan

Personalised recommendations